© Junge

Professor Dr. Nils Hoppe

Professor of Ethics and Law in the Life Sciences, Director of the Center for Ethics and Law in the Life Sciences and Research Dean of the Faculty of Humanities and Social Sciences at Leibniz University Hannover.

Prof. Hoppe teaches, researches and advises on regulatory issues relating to biobanks and tissue banks, tissue engineering, and property law issues in relation to biomaterials. In addition to teaching in Germany, he works as a lawyer for a leading London law firm. Prof Hoppe is a member of Coram Chambers and the Honorable Society of Gray’s Inn.

Thanks to his extraordinary vita with a secondary education and law degrees in England, a doctorate in law in Germany, legal work in London, and his appointment as professor for ethics and law in the life sciences, Prof Hoppe provides extraordinary cross-border interdisciplinary expertise in the fields of medical law, biotechnology law and medical ethics.

The focus of his work also draws on his diverse experience from his work as a board member of the European Association of Health Law, the Editorial Board of the European Journal of Health Law and as a board member of the Open Section Council of the Royal Society of Medicine. In 2010 and 2012 he was visiting scholar at the Center for Health, Law and Emerging Technologies in Oxford. He was an Associate Member of the Mason Institute for Medicine, Life Sciences and the Law at the University of Edinburgh, and a Visiting Professor at the European School of Molecular Medicine Milan and at the Law School of the University of Vienna.

As an advisory board member of MAYRFELD, he supports both us and our clients in regulatory issues in the areas of medical law and biotechnology law, but also in answering ethical questions as an expert and advisor.

When developing novel therapies, developers often find themselves caught in an area of conflict between natural sciences, law, strong regulations and ethics. The greater the innovative strength, the more innovation moves away from known legal and social framework conditions imposing extraordinary challenges on developers, legal practitioners as well as regulators. In the translational process from idea to marketable product, these challenges often may only be overcome by means of intensive interdisciplinary, legal, regulatory and ethical scientific analysis and evaluation, under consideration of all stakeholders’ interests at hand.

We are extremely pleased to welcome Prof Nils Hoppe to our advisory board in his capacity as a truly cross-border and interdisciplinary expert in the areas of biotechnology law and medical ethics.

Upon request, we will be happy to arrange a contact with Prof Hoppe for inquires on his involvement in a consulting project. You may also contact Prof Hoppe directly at nh@hoppe.law.